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LETTER TO THE EDITOR
Fluconazole resistant non-albicans vaginal yeast
in HIV seronegativewomenwith vaginal discharge
in Pune, India
Vaginal candidiasis due to azole-resistant non-C. al-
bicans strains is increasingly seen in women with
vaginitis.1 This study was conducted to assess the
ﬂuconazole susceptibility and potential host fac-
tors associated with vaginal Candida species from
women with vaginal discharge. Vaginal swabs were
obtained from 133 of 186 women who presented
with discharge due to reproductive tract infections
at an STI clinic in a tertiary care government hospi-
tal from April 2001 to August 2002. The swabs were
processed by standard mycological techniques.2,3
Candida isolates obtained were speciated and eval-
uated for in vitro ﬂuconazole susceptibility by broth
microdilution according to standard recommended
guidelines.2,4 Infections were diagnosed by recom-
mended methods5 and HIV testing conducted for
all women based on guidelines issued by the Na-
tional AIDS Control Organisation, India. All proce-
dures and tests were conducted following written
informed consent. Sociodemographic variables and
patient history were recorded in a questionnaire.
Data were analysed using the 2 test (Table 1).
The species distribution and ﬂuconazole suscep-
tibility of 45 candida strains recovered from vaginal
Table 1 Species distribution and susceptibility pro-
ﬁle of candida isolates to ﬂuconazole.
Candida species
(n = 45)
S* (%) S-DD* (%) R* (%)
C. albicans (n = 27) 25 (92.6) 2 (7.4) 0
C. glabrata (n = 12) 5 (41.7) 6 (50) 1 (8.3)
C. krusei (n = 2) 0 2 (100) 0
C. tropicalis (n = 2) 2 (100) 0 0
C. famata (n = 1) 0 1 (100)
C. inconspicua (n = 1) 1 (100) 0 0
Total 33 (73.3) 10 (22.2) 2 (4.4)
* S: susceptible (MIC ≤8g/mL); S-DD: susceptible
dose-dependent (MIC 16—32g/mL); R: resistant (MIC
≥64g/mL).
swabs is shown in Table 1. Twenty-seven (60%) C.
albicans and 18 (40%) non-albicans strains were
identiﬁed of which 12 (66.7%) were speciated as C.
glabrata. The MIC90 of ﬂuconazole against C. albi-
cans and C. glabrata were 4g/mL and 32g/mL
respectively. Although intrinsically resistant to ﬂu-
conazole, observed MICs against C. krusei isolates
(Table 1) were within recommended MIC limits of C.
krusei ATCC 6258 quality control strain used for the
assay.4 Resistant/susceptible dose-dependent sta-
tus was signiﬁcantly associated with non-albicans
candida (P = 0.001). Among host factors anal-
ysed for the species recovered, (HIV serostatus,
age, parity, family planning methods, diagnosis
of vaginal candidiasis, history of discharge in the
previous three months, itching, current use of lo-
cal/systemic azole), non-albicans candida were
marginally associated with HIV seronegative status
(P = 0.06). Women with itching were more likely
to have C. albicans (P = 0.006) and 7/19 (36.8%)
women with vaginal candidiasis had non-albicans
candida (P = 0.712).
Although ﬂuconazole maintained a good activ-
ity against C. albicans, MIC >5g/mL is rare1 and
strains with high MIC90 (4g/mL) indicates a ris-
ing MIC against ﬂuconazole. The large percentage
of C. glabrata isolates, particularly the isolation of
non-albicans species from women with vaginal can-
didiasis, is of concern as these infections are difﬁ-
cult to treat and are often resistant to many azole
antifungal agents.1,6 The association of C. albicans
with HIV seronegative status is similar to a previous
report1 but needs further validation. Such reports
in Indian literature are few and these preliminary
ﬁndings emphasise the need for monitoring suscep-
tibility and to study determinants of azole-resistant
strains, including markers for previous azole expo-
sure, to prevent and control their spread in this
population.
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